Literature DB >> 24530753

Elevated serum levels of lysophosphatidic acid in patients with multiple sclerosis.

Mohammad Balood1, Hamid Zahednasab1, Bahaaddin Siroos2, Seyed Alireza Mesbah-Namin1, Sara Torbati2, Mohammad Hossein Harirchian3.   

Abstract

A plethora of studies have shown that lysophosphatidic acid (LPA) is involved both in inflammation and T cell apoptosis evasion. The aim of this study was to measure the concentrations of LPA in serum of patients with multiple sclerosis (MS). Twenty MS patients along with 20age-sex matched healthy individuals were recruited for this investigation. By employment of ELISA method, we demonstrated that MS patients had higher levels of LPA in serum than control group (P=0.006). This study is the first report of LPA elevation in MS disease.
Copyright © 2014 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24530753     DOI: 10.1016/j.humimm.2014.02.021

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  10 in total

1.  Activation of Macrophages by Lysophosphatidic Acid through the Lysophosphatidic Acid Receptor 1 as a Novel Mechanism in Multiple Sclerosis Pathogenesis.

Authors:  Guillermo Estivill-Torrús; Beatriz García-Díaz; Jennifer Fransson; Ana Isabel Gómez-Conde; Jesús Romero-Imbroda; Oscar Fernández; Laura Leyva; Fernando Rodríguez de Fonseca; Jerold Chun; Celine Louapre; Anne Baron Van-Evercooren; Violetta Zujovic
Journal:  Mol Neurobiol       Date:  2020-09-24       Impact factor: 5.590

2.  Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis - a potential biomarker role for LysoPC.

Authors:  Barbara Rindlisbacher; Cornelia Schmid; Thomas Geiser; Cédric Bovet; Manuela Funke-Chambour
Journal:  Respir Res       Date:  2018-01-10

3.  Lysophosphatidic acid via LPA-receptor 5/protein kinase D-dependent pathways induces a motile and pro-inflammatory microglial phenotype.

Authors:  I Plastira; E Bernhart; M Goeritzer; T DeVaney; H Reicher; A Hammer; B Lohberger; A Wintersperger; B Zucol; W F Graier; D Kratky; E Malle; W Sattler
Journal:  J Neuroinflammation       Date:  2017-12-19       Impact factor: 8.322

4.  Inhibition of lysophosphatidic acid receptor ameliorates Sjögren's syndrome in NOD mice.

Authors:  Eunhye Park; Donghee Kim; Song Mi Lee; Hee-Sook Jun
Journal:  Oncotarget       Date:  2017-04-18

Review 5.  Lysophosphatidic Acid Signaling in Obesity and Insulin Resistance.

Authors:  Kenneth D'Souza; Geena V Paramel; Petra C Kienesberger
Journal:  Nutrients       Date:  2018-03-23       Impact factor: 5.717

Review 6.  Functional Lipids in Autoimmune Inflammatory Diseases.

Authors:  Michele Dei Cas; Gabriella Roda; Feng Li; Francesco Secundo
Journal:  Int J Mol Sci       Date:  2020-04-27       Impact factor: 5.923

7.  Defining Changes in the Spatial Distribution and Composition of Brain Lipids in the Shiverer and Cuprizone Mouse Models of Myelin Disease.

Authors:  Rajanikanth J Maganti; Xiaoping L Hronowski; Robert W Dunstan; Brian T Wipke; Xueli Zhang; Luke Jandreski; Stefan Hamann; Peter Juhasz
Journal:  J Histochem Cytochem       Date:  2018-11-30       Impact factor: 2.479

8.  Autotaxin signaling facilitates β cell dedifferentiation and dysfunction induced by Sirtuin 3 deficiency.

Authors:  Huanyi Cao; Arthur C K Chung; Xing Ming; Dandan Mao; Heung Man Lee; Xiaoyun Cao; Guy A Rutter; Juliana C N Chan; Xiao Yu Tian; Alice P S Kong
Journal:  Mol Metab       Date:  2022-04-06       Impact factor: 8.568

9.  The LPA-CDK5-tau pathway mediates neuronal injury in an in vitro model of ischemia-reperfusion insult.

Authors:  Yaya Wang; Jie Zhang; Liqin Huang; Yanhong Mo; Changyu Wang; Yiyi Li; Yangyang Zhang; Zhaohui Zhang
Journal:  BMC Neurol       Date:  2022-05-02       Impact factor: 2.903

10.  Genetic deletion of Autotaxin from CD11b+ cells decreases the severity of experimental autoimmune encephalomyelitis.

Authors:  Ioanna Ninou; Ioanna Sevastou; Christiana Magkrioti; Eleanna Kaffe; George Stamatakis; Spyros Thivaios; George Panayotou; Junken Aoki; George Kollias; Vassilis Aidinis
Journal:  PLoS One       Date:  2020-04-02       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.